Proton pump inhibitor prescriptions and subsequent use in US veterans diagnosed with gastroesophageal reflux disease

Journal of General Internal Medicine

Volumn 28, Issue 7, 2013, Pages 930-937

  Gawron, Andrew J ^a,b   Pandolfino, John E ^a   Miskevics, Scott ^b   Lavela, Sherri L ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

drug; GERD; prescriptions; Veteran Health Affairs

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; AGED; ARTICLE; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RETROSPECTIVE STUDY; VETERANS HEALTH;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG PRESCRIPTIONS; FEMALE; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES; VETERANS; YOUNG ADULT;

EID: 84879552910     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-013-2345-0     Document Type: Article

References (36)

1. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterol. 2009;136:376-386.
2. Caro JJ, Salas M, Ward A. Healing and Relapse Rates in Gastroesophageal Reflux Disease Treated with the Newer Proton-Pump Inhibitors Lansoprazole, Rabeprazole, and Pantoprazole Compared with Omeprazole, Ranitidine, and Placebo: Evidence from Randomized Clinical Trials. Clin Ther. 2001;23:998-1017.
3. Weijenborg PW, Cremonini F, Smout AJ, et al. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012;24:747-57.
4. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterol. 2008;135:1383-1391.
5. Heidelbaugh JJ, Goldberg KL, Inadomi JM, Suppl. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. 2009;104(Suppl):S27-32.
6. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther. 2000;25:333-340.
7. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care. 2010;16:e228-34.
8. Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170:772-778.
9. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170:784-90.
10. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med. 2010;170:765-771.
11. Kahrilas P. Clinical practice. Gastroesophageal reflux disease. N Engl J Med. 2008;359:1700-1707.
12. American Gastroenterological Association. Choosing Wisely: Five Things Physicians and Patients Should Question. 2012. Available at: http://www.choosingwisely.org/ [Accessed April 6, 2012].
13. Pandolfino JE, Vela MF. Esophageal-reflux monitoring. Gastrointest Endosc. 2009;69:917-30. 930 e1.
14. George CJ, Korc B, Ross JS. Appropriate proton pump inhibitor use among older adults: a retrospective chart review. Am J Geriatr Pharmacother. 2008;6:249-254.
15. Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol. 2006;101:2200-2205.
16. Bradley MC, Fahey T, Cahir C, et al. Potentially inappropriate prescribing and cost outcomes for older people: a cross-sectional study using the Northern Ireland Enhanced Prescribing Database. Eur J Clin Pharmacol 2012.
17. Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf. 2010;19:1019-1024.
18. Gosselin A, Luo R, Lohoues H, et al. The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease. Value Health. 2009;12:34-39.
19. Hungin APS, Hill C, Molloy-Bland M, et al. Systematic review: Patterns of proton pump inhibitor use and adherence in gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2012;10:109-16.
20. Pillans PI, Kubler PA, Radford JM, et al. Concordance between use of proton pump inhibitors and prescribing guidelines. Med J Aust. 2000;172:16-18.
21. Abraham NS, Hartman C, Castillo D, et al. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gastroenterol. 2008;103:323-32.
22. El-Serag HB, Wieman M, Richardson P. The use of acid-decreasing medication in veteran patients with gastro-oesophageal reflux disorder with and without Barrett's oesophagus. Aliment Pharmacol Ther. 2008;27:1293-1299.
23. El-Serag HB. Temporal trends in new and recurrent esophageal strictures in Department of Veterans Affairs. Am J Gastroenterol. 2006;101:1727-33.
24. Yang Y-X, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947-53.
25. Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106:1209-18. quiz 1219.
26. Abraham NS, El-Serag HB, Johnson ML, et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterol. 2005;129:1171-1178.
27. Gurbel PA, Tantry US. Antiplatelet therapy: Clopidogrel-PPI interaction, an ongoing controversy. Nat Rev Cardiol. 2011;8:7-8.
28. Van Soest EM, Siersema PD, Dieleman JP, et al. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther. 2006;24:377-385.
29. El-Serag HB, Fitzgerald S, Richardson P. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study. Am J Gastroenterol. 2009;104:2161-2167.
30. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83.
31. Gadzhanova SV, Roughead EE, Mackson JM. Initiation and duration of proton pump inhibitors in the Australian veteran population. Intern Med J 2010.
32. Inadomi J, McIntyre L, Bernard L, et al. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol. 2003;98:1940-1944.
33. Ostini R, Jackson C, Hegney D, et al. How is medication prescribing ceased? A Systematic Review. Medical Care. 2011;49:24-36.
34. Hershcovici T, Fass R. An algorithm for diagnosis and treatment of refractory GERD. Best Pract Res Clin Gastroenterol. 2010;24:923-936.
35. Dickman R, Boaz M, Aizic S, et al. Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded. J Neurogastroenterol Motil. 2011;17:387-94.
36. Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterol. 2008;135:1392-1413.